恩瑞格国内售价多少钱？

In 2010, it was approved for marketing in China and is approved for the treatment of chronic iron overload caused by frequent blood transfusions in beta-thalassemia patients aged 2 years and above and chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndrome aged 10 years and above.

So, how much does Enrig sell for in China?

It is understood that the price of Enrig in China is relatively high, with a box costing about $2,000. A normal person weighing 60kg would cost more than 24,000$ to take Enrige for a month. Ordinary families will pay this price for a long time.

Novartis of Switzerland imports Enriga to India, the specification is 400mg*30 tablets/box, and the price is about $700.

The specification of Enrego produced by Indian pharmaceutical factory is 500*30 tablets/box, and the price is about 500$. Patients can choose different versions of Enrego according to their own conditions. Due to the floating exchange rate, the price will be different. Please consult the medical companion for the specific price!

Iron overload is treated by giving Enriga, which drives iron deposits into soluble complexes that can be excreted from the body. Many patients, such as those with thalassemia, sideroblastic anemia, myelodysplastic syndrome and aplastic anemia, require long-term blood transfusion treatment, which leads to increased iron deposition in the body and secondary transfusion-related iron overload, which causes tissue damage and functional damage to multiple organs. Cardiac complications including myocardial infarction, congestive heart failure, and arrhythmia are the most common causes of death.

It is a new type of iron removal treatment based on directional binding of iron ions in the body, effectively increasing iron excretion, reducing iron content in the body and its pathological deposition in various organs. It is also the only effective drug for the treatment of iron overload at present. The application of Enrig has greatly reduced the mortality rate and improved the quality of life of patients with long-term blood transfusions, and its clinical application has been receiving widespread attention and attention.